참가신청

HOME  >  교육 및 행사  >  참가신청
교육명 [일정 변경 안내] BioCon China 2020 분류 기타
신청일정 2020.03.18~2020.06.30 행사일정 2020.07.07~2020.07.09
장소 상해 시간

상세안내



Join 7th BioCon China 2020, the most influential regional biopharma event, to meet with 2000+  industry peers from discovery, CMC, clinical, process development and manufacturing!


BioCon China is dedicated to establishing a robust idea-exchanging and business-cooperating platform for global regulatory agencies, and worldwide leading biotech companies and Asian biopharmaceutical enterprises. In the previous activities, BioCon China has accumulated 4000+ global industrial participants, 320+ leading products, solution and service providers, and 450+prominent speakers to join the annual grand events.



[Brief Event Informaion]

Name: 7th International Biopharmaceutical Convention (BioCon China 2020)

Venue: Shanghai Convention & Exhibition Center of International Sourcing, Shanghai, China (상하이 국제 소싱 전시 컨벤션 센터)

Event Date: July 7-9, 2020

Event website : https://www.bagevent.com/event/2645679?bag_track=KOBIA

Event Organizer Name: BMAP Global

Contact Information (with country & area code): +86 18017939885

Email ID: biocon@bmapglobal.com




Conference Overview

Conference Structure

In the context of international ICH, China's biopharmaceutical industry has entered a critical moment: how to develop the next generation of new therapeutic biological products? How to realize the layout, R & D and application of differentiated biological innovative drugs (antibodies, therapeutic vaccines, cell products, gene therapy virus products)? How to achieve the process improvement and process change of biological products under the condition of meeting the supervision? How to accelerate the clinical development of bio-innovative drugs and similar drugs? What factors need to be considered in large-scale production of biopharmaceuticals and plant construction?

As the annual event with the highest participation of Chinese biopharmaceutical companies, the 7th International Biopharmaceutical Congress and Biotechnology Instrumentation and Reagent Exhibition of BioCon2020 will be upgraded and launched on July 7-9, 2020 at the Shanghai International Purchasing Convention Center High quality, deeper level, grasp the latest global weathervane, focus on the latest regulatory trends, explore the frontier development strategies of biopharmaceuticals, from new drug discovery to drug development, from laboratory to industrialization, from preclinical development to clinical development, From process development to commercial production, from process improvement to process change, from pipeline project to product launch, the whole cycle and process , to build a comprehensive domestic and foreign policy discussion, technology exchange, product display, and project cooperation for the Chinese biopharmaceutical industry Professional platform to explore the core trends of the industry and promote the full speed of the biomedical industry!





What’s New in BioCon 2020?

  • Interpreting the latest guidelines of global regulations and China's new policies to help biopharma companies to navigate in the changing regulatory environment

  • Focusing on the development of hot product portfolios -- the next generation of polyclonal antibodies, ADC, nano-antibodies, cell therapy, oncolytic viruses, recombinmant proteins and etc. 

  • Sharing the best practices of global product submissions with multi-centerclinical trials worldwide

  • Analyzing the latest discoveries and achievements of combined therapy for cancer

  • Introducing the application of new antibody development platforms to improve R&D efficiency with lower cost 

  • Discussing the optimized bioprocess changing paths and the supervision of post-process changing requirements

  • Exploring cost-effective biopharma plant design and construction in compliance with GMP requirements


 Previous guests
Academician of the Chinese Academy of Engineering
Wang Junzhi
Academician of Chinese Academy of Engineering
 
Stephen W. Drew, Academician of the American Academy of Engineering and former Vice President of the United States
Stephen W. Drew
Academician of the American Academy of Engineering, former vice president of Merck
 
Luo Jianhui, Minister of Pharmacy, National Pharmaceutical Review Center
Luo Jianhui
Minister of Pharmacy, National Pharmaceutical Review Center
 
Shen Qi, Director of China Food and Drug Inspection Institute
Shen Qi
Director of China Food and Drug Inspection Institute
 
Angela Thomas, Vice Chairman, EMA Human Drugs Committee
Angela Thomas
Vice Chairman of EMA Human Drug Committee
 
Elena Wolff-Holz, Chair, EMA Biosimilars Expert Panel, Medical Reviewer, German Federal Institute of Biomedicine
Elena Wolff-Holz
Chairman of the EMA Expert Group on Biosimilars, Medical Reviewer, German Federal Institute of Biomedicine
 
Niklas Ekman, Member of the EMA Biosimilars Guidelines Expert Group, National Medicines Agency of Finland
Niklas Ekman
Member of the Finnish National Medicines Agency, EMA Biosimilar Guide
 
Venke Skibeli, Clinical Reviewer, Norwegian Pharmacy Agency, Member of the EMA Expert Committee on Biosimilars Guidelines
Venke Skibeli
Clinical reviewer of the Norwegian Pharmacy Agency and member of the EMA Expert Committee on Biosimilars
 
Alex Kudrin, Former Medical Reviewer of Biological Products, Former Vice President and Global Development Leader of Celltrion
Alex Kudrin
Former medical reviewer of biological products of the UK Food and Drug Administration, former vice president of Celltrion, and head of global development
 
He Ruyi, Former Chief Scientist of CDE
He Ruyi
CDE Former Chief Scientist
 
Baihe, Department of Biological Products, State Drug Administration
white crane
Biological Products Division, Drug Registration Administration Department, State Drug Administration
 
Rao Chunming, Director of the Recombinant Drugs Office of the Institute of Biotechnology, China
Rao Chunming
Director of the Reconstituted Drugs Division of the Bioassay of the Chinese Academy of Sciences, Executive Member of the National Pharmacopoeia
 
Wang Chong, Leader of Biological Group, Shanghai Drug Evaluation and Verification Center
Wang Chong
Leader of Biological Group, Shanghai Drug Evaluation and Verification Center
 
Mark McCamish, former president of global biopharmaceutical & oncology drug development at Sandoz
Mark McCamish
Sandoz Former President, Global Biopharmaceutical & Oncology Drug Development
 
Patrick Liu, TEVA's former vice president of global biological product development
Patrick Liu
TEVA Former Vice President of Global Biological Product R & D
 
Hans-Martin Mueller, director of process development for biosimilars at Merck, Switzerland
Hans-Martin Mueller
Director of Process Development, Biosimilar, Merck, Switzerland
 
Steven Lee, Former Vice President and General Manager of BMS, Founder and CEO of BioGENEXUS Group LLC
Steven Lee
Former Vice President and General Manager of BMS, Founder and CEO of BioGENEXUS Group LLC
 
Katrin Rupalla, former head of China R & D at BMS
Katrin Rupalla
Former head of China R & D at BMS
 
Zhang Lianshan, Director, Senior Deputy General Manager and Global R & D President of Jiangsu Hengrui Pharmaceutical Co., Ltd.
Zhang Lianshan
Director, Senior Deputy General Manager and Global R & D President of Jiangsu Hengrui Pharmaceutical Co., Ltd.
 
Liu Shigao, Co-founder, President and CEO of Shanghai Fuhong Hanlin Biotechnology Co., Ltd.
Liu Shigao
Co-founder, President and CEO of Shanghai Fuhong Hanlin Biotechnology Co., Ltd.
 
Li Ning, CEO of Shanghai Junshi Biomedical Technology Co., Ltd.
Li Ning
CEO of Shanghai Junshi Biomedical Technology Co., Ltd.
 
Li Kang, Senior Vice President and Chief Director of Biopharma
Li Kang
Senior Vice President and Chief Director of Biopharma
 
Xu Wei, Senior Vice President of Cinda Bio
Xu Wei
Senior Vice President of Cinda Bio
 
Jianwei Zhu, Dean of School of Pharmacy, Shanghai Jiaotong University, Director of Engineering Research Center of Cell Engineering and Antibody Drugs, Ministry of Education
Zhu Jianwei
Dean of School of Pharmacy, Shanghai Jiaotong University, Director of Engineering Research Center of Cell Engineering and Antibody Drugs Ministry of Education
 
Demin Zhou, Dean of School of Pharmacy, Peking University
Zhou Demin
Dean, School of Pharmacy, Peking University
 
Shi Yuankai, Deputy Director, National Cancer Center, Deputy Dean, Cancer Hospital, Chinese Academy of Medical Sciences
Shi Yuankai
Deputy Director, National Cancer Center, Vice President, Cancer Hospital, Chinese Academy of Medical Sciences
 
Zhou Caicun, Director of Oncology, Shanghai Lung Hospital, Tongji University
Zhou Caicun
Director of Oncology, Shanghai Lung Hospital, Tongji University
 
Meng Shufang, Cell Researcher, Institute of Biological Products Testing, China Academy of Food and Drug Testing
Meng Shufang
Researcher, Cell Division, Institute of Biological Products Assay, China Food and Drug Administration
 
Yuan Baozhu, Researcher, Cell Resource Center, China Food and Drug Testing Institute
Yuan Baozhu
Director, Researcher, Cell Resource Center, China Food and Drug Testing Institute
 
Professor Zhang Shuren, Professor of Cancer Hospital, Chinese Academy of Medical Sciences, and Drug Evaluation Expert of State Drug Administration
Uncle Zhang
Professor of Cancer Hospital of Chinese Academy of Medical Sciences, Expert of Drug Evaluation of State Drug Administration
 
Fan Xiaohu, Co-founder and Chief Scientific Officer of Nanjing Legend Biotechnology Co., Ltd.
Fan Xiaohu
Co-founder and Chief Scientific Officer of Nanjing Legend Biotechnology Co., Ltd.
 
J. Joseph Melenhorst, Director of Cellular Immunotherapy Product Development, University of Pennsylvania
J. Joseph Melenhorst
Director of Cellular Immunotherapy Product Development, University of Pennsylvania
 
Juno Chief CMC Regulation Policy and Strategy Leader Michael G. Covington
Michael G. Covington
Juno Chief CMC Regulatory Policy and Strategy Leader
 
Cui Weidong, Chief Technology Officer, Fosun Kate Biotech
Cui Weidong
Chief Technology Officer, Fosun Kate Biotech
 
Liu Binlei, Chairman of Wuhan Binhui Biotechnology Co., Ltd.
Liu Binlei
Chairman of Wuhan Binhui Biotechnology Co., Ltd.




Testimonials


  • Very satisfied with the event and full of harvest. – Sanofi

  • Very good, the content of the speech is well organized. – Asymchem Inc

  • Speakers are very professional, and the conference is well organized with focusing on detail. -- Boehringer Ingelheim Biopharmaceutical (China) Co., Ltd.

  • Very good, the content of the speech is well organized. -- Asymchem Inc

  • The conference scale is relatively good, and it fits with our company very well. --- Sino Biological Inc.

  • Very good peer exchange platform, which will accelerate the development of the domestic biomedical industry. -- GE

  • Through attending this conference, I have gained a lot. I also met many peers, and learned a lot of experience and knowledge, especially in the field of new drugs -- QYuns Biomedical Co., Ltd.

  • Excellent event and management. The selection and content of the topic have been carefully considered and fit the popular issues in the industry. -- Zhejiang Teruisi Pharmaceutical Co., Ltd.

  • Very good. Speakers and attendees are all from well-known organization in the industry. Hence it is very helpful in opening practical ideas up. -- XINTRUM Pharmaceuticals, Deputy Director of Technology



Contact us
T: 86 180 1793 9885
E:
biocon@bmapglobal.com
W: www.bmapglobal.com/biocon2020